Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Fibrotic response in the human lens capsular bag after implantation of a new hydrophobic aspheric intraocular lens

Search Title by author or title

Session Details

Session Title: IOL Dislocation & Opacification

Session Date/Time: Tuesday 25/09/2018 | 14:00-16:00

Paper Time: 14:48

Venue: Room A3, Podium 1

First Author: : A.Hillenmayer GERMANY

Co Author(s): :    C. Wertheimer   S. Kassumeh   A. Ohlmann   A. von Studnitz   S. Priglinger   W. Mayer     

Abstract Details

Purpose:

Fibrotic responses in the human capsular bag play a key role in the formation of posterior capsule opacification after cataract surgery and is influenced by IOL design and material. The following is an in vitro comparison between the new monofocal Alcon Clareon IOL vs. the standard Acrysoft.

Setting:

Cell and molecular biology research lab at the Department of Ophthalmology, Ludwig-Maximilians-University Munich

Methods:

We cultivated 20 cadaver capsular bags from 10 human donors under standard cell culture conditions. For the preparation of the capsular bag two groups were established: One group was implanted with the clareon IOL the other received the Acrysoft IOL. Cellular growth of lens epithelial cells was observed and photo-documented. The days until full cell-coverage of the posterior capsule were documented. Capsular bags were stained for fibronectin, alpha smooth muscle actin (α-SMA), and collagen type 1.

Results:

The currently running evaluation revealed comaprable cell growth patterns for both IOL. Until now we could not detect any statistically significant differences in the time points measured. Further analysis and results of fibrotic markers for the new IOL platform will be presented at the ESCRS.

Conclusions:

Due to its optimized design, the new Clareon IOL does not show increased fibrotic reactivity in vitro. We expect similar behavior in a clinical setting.

Financial Disclosure:

... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous